Bladder Cancer
New Mental Health Diagnosis as a Prognostic Factor for Muscle-Invasive Bladder Cancer.
December 1, 2022
Multiparametric MRI for Diagnosis and Staging of Bladder Cancer - Expert Commentary
November 30, 2022
Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis.
November 30, 2022
Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.
November 30, 2022
Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
November 30, 2022
Genentech Provides Update on Tecentriq U.S. Indication for Previously Untreated Metastatic Bladder Cancer
November 29, 2022
Perioperative and Oncologic Outcomes Associated with Simultaneous Radical Cystectomy and Nephroureterectomy.
November 29, 2022
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
November 28, 2022
Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?
November 28, 2022
Treatment decisions of bladder cancer in patients older than 85 years: a SEER-based analysis 2011-2015.
November 25, 2022
Positive Predictive Values of Procedure Codes on the Treatment of Non-Muscle Invasive Bladder Cancer in the Danish National Patient Registry.
November 25, 2022
Complications in urological surgery: Bladder surgery.
November 24, 2022
Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship.
November 23, 2022